ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2018
Obesity and nonalcoholic fatty liver disease: current perspectives.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06348628 (Motivational Interviewing for Weight Loss in the Management of Non Alcoholic Fatty Liver Disease - A Randomized Controlled Trial), which is not on this map. Cited by 130 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Motivational Interviewing for Weight Loss in the Management of Non Alcoholic Fatty Liver Disease - A Randomized Controlled Trial
Who cites it
130 citing papers in PubMed, 3 syntheses or guidelines pooled it, 231 citations in OpenAlex.
- Garlic supplementation for the treatment of chronic liver disease: a meta-analysis of randomized controlled trials.African health sciences · 2023Pooled it
- Comparison of the Effect of Endurance, Strength and Endurance-Strength Training on Glucose and Insulin Homeostasis and the Lipid Profile of Overweight and Obese Subjects: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- Outcomes of Bariatric Surgery in Patients with Liver Cirrhosis: a Systematic Review.Obesity surgery · 2021Pooled it
- Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.Hepatology communications · 2024Trial
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers.Clinical pharmacology in drug development · 2020Trial
- Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial.BMC gastroenterology · 2019Trial
- Effects of Non-Alcoholic Fatty Liver Disease on the Inpatient Outcomes of Patients Admitted for Atrial Fibrillation: An Analysis from the National Inpatient Sample Database (NIS 2016-2019).Journal of cardiovascular development and disease · 2026Article
- Article
- NGR1 Ameliorates Hepatocyte Steatosis and Mitochondrial Dysfunction Associated with the Restoration of NDUFS2.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Genetic and non-genetic drivers of histological progression and regression in MASLD.Journal of hepatology · 2026Article
- Impact of meal frequency on gastroesophageal reflux disease following laparoscopic sleeve gastrectomy.Frontiers in surgery · 2026Article
- Differences in gene expression may contribute to the racial differences in the risk of MASLD.PloS one · 2026Article
- Obesity surgery improves metabolic dysfunction-associated steatotic liver disease and type 2 diabetes - MRI and biochemical analysis of liver and pancreas.Surgery open science · 2026Article
- Endo-hepatology: Bridging the gap between lumen and liver.World journal of gastroenterology · 2025Review
- Myeloid ADAM17 induces ST2Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis.Genes & diseases · 2025Article
- Beyond GLP-1 Agonists: An Adaptive Ketogenic-Mediterranean Protocol to Counter Metabolic Adaptation in Obesity Management.Nutrients · 2025Review
- Article
- M6A methyltransferase METTL3 promotes glucose metabolism hub gene expression and induces metabolic dysfunction-associated steatotic liver disease (MASLD).BMC genomics · 2025Article
- Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.International journal of molecular sciences · 2025Review
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation for drug development with the focus on metabolic pathways, inflammation, and slowing or reversing fibrosis. There are several agents advancing in clinical trials, and promising results have been seen with drugs that affect hepatic steatosis, inflammation, and fibrosis. This review will provide an overview on NAFLD and some of the mechanisms of disease that are being targeted with pharmacologic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.